Hypophosphatasia News and Research

RSS
Alexion initiates new global Uncommon Strength campaign to raise awareness of rare diseases

Alexion initiates new global Uncommon Strength campaign to raise awareness of rare diseases

Strensiq approved for treatment of patients with juvenile-onset HPP

Strensiq approved for treatment of patients with juvenile-onset HPP

Japanese researchers explore use of bone marrow transplants to treat hypophosphatasia

Japanese researchers explore use of bone marrow transplants to treat hypophosphatasia

Enzyme therapy may prevent skeletal abnormalities associated with neurofibromatosis type-1

Enzyme therapy may prevent skeletal abnormalities associated with neurofibromatosis type-1

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Asfotase alfa gets Breakthrough Therapy designation from FDA for treatment of patients with HPP

Asfotase alfa gets Breakthrough Therapy designation from FDA for treatment of patients with HPP

Osteopontin plays a role in X-linked hypophosphatemia

Osteopontin plays a role in X-linked hypophosphatemia

Alexion second quarter net product sales increase to $274.7 million

Alexion second quarter net product sales increase to $274.7 million

Doctors identify promising new treatment for hypophosphatasia

Doctors identify promising new treatment for hypophosphatasia

Alexion to acquire 100% of capital stock of Enobia

Alexion to acquire 100% of capital stock of Enobia

Enobia raises US$40M through private placement

Enobia raises US$40M through private placement

Enobia completes patient enrollment in ENB-0040 Phase II study for HPP

Enobia completes patient enrollment in ENB-0040 Phase II study for HPP

Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia

Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia

Enobia announces positive results from ENB-0040 Phase II juvenile clinical trial for hypophosphatasia

Enobia announces positive results from ENB-0040 Phase II juvenile clinical trial for hypophosphatasia

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Enobia reports positive interim data from ENB-0040 enzyme replacement therapy study for children with HPP

Enobia reports positive interim data from ENB-0040 enzyme replacement therapy study for children with HPP

Enobia Pharma unveils findings from first HPP self-reported patient survey at ACMG 2010

Enobia Pharma unveils findings from first HPP self-reported patient survey at ACMG 2010

McGill, Enobia Pharma collaborate to develop treatments for serious genetic bone diseases

McGill, Enobia Pharma collaborate to develop treatments for serious genetic bone diseases

Enobia Pharma initiates study of bone-targeted enzyme replacement therapy for hypophosphatasia

Enobia Pharma initiates study of bone-targeted enzyme replacement therapy for hypophosphatasia

Enobia Pharma's clinical study of ENB-0040 for treating hypophosphatasia provides positive results

Enobia Pharma's clinical study of ENB-0040 for treating hypophosphatasia provides positive results